CPC A61K 35/17 (2013.01) [A61K 31/167 (2013.01); A61K 31/4965 (2013.01); A61K 35/15 (2013.01); A61P 35/02 (2018.01); A61K 31/69 (2013.01); A61K 2300/00 (2013.01)] | 17 Claims |
1. A method of potentiating chimeric antigen receptor-modified immune cells (CAR-MIC) cancer immunotherapy comprising administering at least one differentiating retinoic acid receptor (RAR) active agent, wherein the differentiating RAR active agent is a RARα agonist, to a cancer patient who is receiving, has received, or is scheduled to receive, CAR-MIC, wherein the RARα agonist is a CYP26 metabolism-resistant, RARα selective agonist having a structure of general formula (I)
wherein R1 is H or C1-6 alky, R2 and R3 are independently H or F, and R4 is a halogen;
wherein the RARα agonist is administered daily.
|